ArticleBioinformatics (Oxford, England)2026
A linear interpretable model for drug target prediction.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationIdentifying drug targets is fundamental in drug development, both for discovering new therapies and for ensuring effective and safe treatments. Drug-target interactions (DTIs) have been predicted using machine learning approaches that integrate heterogeneous data; however, often these models are complex and lack interpretability.
resultsWe investigate whether a simple, fully interpretable linear model can achieve competitive performance for DTI prediction. We propose Linear Interpretable Drug-Target Interaction (LI-DTI), a prediction model inspired by recommender systems. LI-DTI learns from different drug-drug and target-target similarity matrices and provides interpretable predictions as a linear combination of these similarity measures. We show that LI-DTI can recover DTIs even when drugs or targets have no previously known interactions, across multiple cross-validation settings. We further evaluate performance while mitigating potential bias arising from high chemical similarity between drugs or sequence similarity between targets. Finally, we assess LI-DTI in a prospective evaluation, training on DTIs present in DrugBank from 2011 and testing on interactions added through 2022. Across all evaluations, LI-DTI achieves state-of-the-art performance while producing interpretable predictions. For practical use, we provide a web-based tool that enables users to visualize individual LI-DTI predictions for DrugBank (2025) and inspect the biological evidence underlying them. Our results indicate that simple linear models with well-curated similarity features can deliver robust and interpretable DTI predictions, facilitating hypothesis generation and downstream experimental prioritization. AVAILABILITY AND IMPLEMENTATION: Code and data available at https://github.com/paccanarolab/LI-DTI. Web tool available at https://paccanarolab.org/lidtiweb/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.